Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh

- 3 Jahan Ara¹, Md. Sirazul Islam^{2,3}, Md. Tarek Ul Quader⁴, Anan Das¹, F. M. Yasir Hasib^{2,5},
- 4 Mohammad Saiful Islam⁶, Tazrina Rahman⁷, Seemanta Das¹, M.A. Hassan Chowdhury⁸, Goutam
- 5 Buddha Das^{3,9}, and Sharmin Chowdhury^{1,2,3.}
- ⁶ ¹One Health Institute, Chattogram Veterinary and Animal Sciences University, Khulshi-4225,
- 7 Chattogram, Bangladesh;
- 8 ²Department of Pathology and Parasitology, Faculty of Veterinary Medicine, Chattogram
- 9 Veterinary and Animal Sciences University, Khulshi-4225, Chattogram, Bangladesh;
- 10 ³COVID-19 Detection Laboratory, Chattogram Veterinary and Animal Sciences University,
- 11 Khulshi-4225, Chattogram, Bangladesh;
- ⁴Department of Anesthesiology and ICU, Chittagong Medical College Hospital, Chattogram,
- 13 Bangladesh;
- ⁵Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong
- 15 SAR;
- ⁶Department of Emergency and Accident, Imperial Hospital Limited, Chattogram, Bangladesh;
- ¹⁷ ⁷Department of Microbiology and Virology, Chittagong Medical College, Chattogram,
- 18 Bangladesh;
- ⁸Department of Medicine, Chittagong Medical College, Chattogram, Bangladesh;
- ⁹Department of Animal Science and Nutrition, Chattogram Veterinary and Animal Sciences
- 21 University, Khulshi-4225, Chattogram, Bangladesh.
- 22

23 * Corresponding author:

24 Sharmin Chowdhury, PhD

25 Director, One Health Institute, Chattogram Veterinary and Animal Sciences University, Khulshi,

- 26 Chattogram-4225.
- 27 E-mail: sharminchowdhury@cvasu.ac.bd
- 28

29 Abstract

Background: Seroprevalence studies of coronavirus disease 2019 (COVID-19) assess the degree
of undetected transmission in the community. Different groups, such as healthcare workers
(HCWs), garment workers, and others, are deemed vulnerable due to their workplace hazards and
immense responsibility.

Purpose: The present study was conducted to estimate the seroprevalence of anti-SARS-CoV-2 antibody (IgG) and its association with different explanatory variables. Further, the antibody was quantified to assess the increasing or decreasing trend over different intervention periods and according to other factors.

Methodology: This cross-sectional study observed health workers - doctor, nurse, hospital staff, etc. in and outpatients (non-COVID-19) and garments workers of Chattogram metropolitan area (CMA, N=748) from randomly selected six government and private hospitals and two garment factories. Study subjects were included upon written consent, fulfilling specific inclusion criteria. Venous blood was collected following standard aseptic methods. Qualitative and quantitative ELISA was used to identify and quantify antibodies (IgG) in serum samples. Descriptive, univariable, and multivariable statistical analysis was performed.

45 Results: Overall seroprevalence was estimated as 66.99% (95% CI: 63.40%-70.40%).
46 Seroprevalence among HCWs, in and outpatients, and garments workers were 68.99% (95% CI:

 respectively. Scroprevalence was 44.47 % (95% CI: 38.6%-50.4%) in the non-vaccinated population while it was significantly (<i>p</i> <0.001) higher in the population receiving the first dose (61.66 %, 95% CI: 54.8%-68.0%) and both (first and second) doses of vaccine (100%, 95% CI: 98.4%-100%). The mean titer of the antibody was estimated as 255.46 DU/ml and 159.08 DU/ml in the population with both doses and one dose of vaccine, respectively, compared to 53.71 DU/ml of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time after vaccination was observed. Conclusions: Scroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the scroprevalence and titer, which decreased to a certain level over time. Although antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 (61.66 %, 95% CI: 54.8%-68.0%) and both (first and second) doses of vaccine (100%, 95% CI: 98.4%-100%). The mean titer of the antibody was estimated as 255.46 DU/ml and 159.08 DU/ml in the population with both doses and one dose of vaccine, respectively, compared to 53.71 DU/ml of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time after vaccination was observed. Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 98.4%-100%). The mean titer of the antibody was estimated as 255.46 DU/ml and 159.08 DU/ml in the population with both doses and one dose of vaccine, respectively, compared to 53.71 DU/ml of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time after vaccination was observed. Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 in the population with both doses and one dose of vaccine, respectively, compared to 53.71 DU/ml of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time after vaccination was observed. Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time after vaccination was observed. Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 after vaccination was observed. Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 Conclusions: Seroprevalence and mean antibody titer varied according to different factors in this study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 study. The second dose of vaccine significantly increased the seroprevalence and titer, which decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 decreased to a certain level over time. Although antibody was produced following natural infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 infection, the mean titer was relatively low compared to antibody after vaccination. This study emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 emphasizes the role of the vaccine in antibody production. Based on the findings, interventions like continuing extensive mass vaccination of the leftover unvaccinated population and bringing the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 60 like continuing extensive mass vaccination of the leftover unvaccinated population and bringing 61 the mass population with a second dose under a third dose campaign might be planned. 62 63 Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 the mass population with a second dose under a third dose campaign might be planned. Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
 62 63 Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
63 Keywords: Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG
64
65 Introduction
66 Chattogram, the port city of Bangladesh, is classified as a high-risk zone for SARS-CoV-2 contact
transmission and is one of the most crowded economic and trading centers [1]. On April 3, 2020,

69 followed by the first death on 9 April [3]. The disease can manifest itself in various ways, from

68

Chattogram city witnessed its first Coronavirus Disease 2019 (COVID-19) positive case [2],

asymptomatic and minor upper respiratory symptoms to severe pneumonia and acute respiratory
distress syndrome [4]. While nucleic acid amplification, such as polymerase chain reaction (PCR),
is the gold standard for diagnosing acute SARS-CoV-2 infection and is widely recommended, the
antibody-based approach improves diagnosis accuracy by capturing asymptomatic testing and
recovered infections [5].

During an infectious disease outbreak, seroprevalence investigations are crucial in revealing 75 undetected infection in the population and preventing post-pandemic reappearance [6]. 76 Determining the actual burden of infection is also vital for epidemic forecasting and response 77 78 planning. Seroprevalence studies are potent in identifying the number of undiagnosed missing cases with mild or no symptoms or who cannot undergo testing that may contribute significantly 79 80 to the transmission [7-11]. Further, seroprevalence studies estimate the susceptible population in a 81 community. A current investigation discovered that up to 23% of the patients diagnosed with COVID-19 from December 2020 to February 2021 in Bangladesh were asymptomatic [12]. Thus, 82 antibody testing could be crucial to determine the actual SARS-CoV-2 exposure rates since PCR 83 only identifies the viral nucleic acid in individuals with existing symptoms [13]. 84

85 According to numerous research, seropositivity fluctuates considerably depending on parameters 86 such as location and time [7, 14]. Antibody titers reach their peak one month after the onset of symptoms, and their levels are directly proportional to the severity of the illness [15]. Titers 87 continue to fall after that, with IgM and IgA titers falling fast and IgG titers falling more slowly 88 [16]. However, a greater understanding of antibody responses to SARS-CoV-2 after natural 89 infection might aid in the development of more successful vaccination strategies in the future. 90 Bangladesh started administering COVID-19 vaccinations on January 27, 2021, and mass 91 92 immunization commenced on February 7, 2021 [17, 18]. As of December 21, 2021, 50.27% of the

target population had received the first dose, and 34.60% received the second dose [19].
Bangladesh has already started administering third doses to senior persons aged 60 and up, people
with comorbidities, and frontline workers. [20]. According to a web-based anonymous crosssectional survey conducted among the general Bangladeshi population between January 30 and
February 6, 2002, 61.16% of respondents were inclined to accept/take the COVID-19 vaccine [21].
However, vaccination coverage and seroprevalence among the general public must be investigated
nationwide to know the herd immunity.

In the COVID-19 pandemic, HCWs are facing immense challenges worldwide. Occupational 100 101 exposures among HCWs have been documented in numerous nations as worrying [22]. Likewise, COVID-19 has had a significant impact on the healthcare system of Bangladesh. According to the 102 103 latest data from the Bangladesh Medical Association, between March 8, 2020, and November 11, 2021, 9455 HCWs, including physicians, nurses, and other staff, were infected with COVID-19, 104 as well as 188 doctors died as a result [23]. Front liners directly involved in diagnosing, treating, 105 and caring for COVID-19 patients are at risk of physical and psychological distress [24-29]. 106 Similarly, workers in the garment industry confront different problems in the workplace all around 107 the world. According to the Bangladesh Garment Manufacturers and Exporters Association 108 109 (BGMEA), 4500 garment companies employ over 4.5 million people or nearly 2.5 percent of the country's entire population [30]. The bulk of the industries operate with limited space, making it 110 111 challenging to enforce physical distancing norms [31]. SARS-CoV-2 transmission might be exacerbated by crowded workplaces, transportation, and lack of physical distancing [32]. Hence, 112 it is necessary to put in place measures including risk management in the workplace, vulnerable 113 employee care, the development of an occupational surveillance system, and vaccination policy 114

administration to address the COVID-19 issues [33, 34]. Thus, knowing the true seroprevalence
both in the risk groups and community might assist in planning interventions efficiently.

In this study, we reported population-based SARS-CoV-2 seropositivity among HCWs, indoor and outdoor patients of various government and private hospitals, and garment workers of CMA, as determined by enzyme-linked immunosorbent assay (ELISA). Moreover, we measured the antibody titer, and both outcomes (seropositivity and antibody titer) were tested to know the association of different factors.

122 Materials and Methods

123 Study design and setting

From February to September 2021, we conducted a cross-sectional population-based study among 124 HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor 125 and outdoor patients (non-COVID-19) of six government and private hospitals each, and two 126 127 garment factories in CMA. All hospitals belonging to the study area were stratified according to their affiliation status; government and private. From each stratum, six hospitals were randomly 128 selected. Sample size was calculated considering the following parameter: 0.65 proportion, 5% 129 130 margin of error, 95% confidence limit and design effect 2. Each organization's human resources department provided a list of personnel. Following a simple random sampling technique, samples 131 132 were collected from a total of 748 respondents.

We interviewed participants to collect information after receiving written consent. Answering a questionnaire and taking blood to test SARS CoV-2 antibodies were part of the study procedure. Our study followed a World Health Organization protocol for population-level COVID-19 antibody testing [**35**]. The questionnaire included sociodemographic details and factors

hypothesized to be associated with seropositivity. Participants were included in the study based onseveral inclusion criteria.

- 139 Inclusion criteria:
- Asymptomatic: Only an asymptomatic group was included to ensure the presence of
 antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny
- nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection
- In case of having past confirmed COVID-19 status (by Rt PCR):
- i. Participants who had already passed at least 28 days after a negative Rt-PCR test.
- ii. Participants who did not take a repeated test to ensure negativity had passed at least 42
 days after the first COVID-19 test.
- 147 Besides, persons under 18 were excluded, as were those with an incomplete questionnaire.

148 Baseline blood collection and processing

Heparinized blood specimens (6mL) were collected and transported to the clinical pathology
laboratory (CPL) of Chattogram Veterinary and Animal Sciences University (CVASU) within
three hours of collection. The serum was separated to evaluate the IgG antibody and kept at -20 °C
until serological investigation.

153 Serological test examination

Antibody was determined by a commercial qualitative assay using COVID-19 IgG ELISA test (Beijing Kewei Clinical Diagnostic Reagent Inc., China; Ref: 601340) as per the manufacturer's instructions. The assay is an enzyme-linked immunoassay (ELISA) that detects IgG against the SARS-CoV-2. An index (Absorbance/Cutt-off) of <1 was interpreted as negative, 0.9 to 1.1 as

borderline (retesting of these specimens in duplicates was done to confirm results), and ≥ 1 index as positive. Per the manufacturer, the sensitivity and specificity of the assay for IgG are 93.8% and 97.3%, respectively. Positive and negative controls were included in all assay batches. Repeated testing using the same specimen yielded the same interpretation.

The concentration of IgG antibodies was determined by SARS-CoV-2 S1-RBD IgG (DiaSino® 162 163 Laboratories Co., Ltd. Zhengzhou, China, Ref: DS207704), which is based on enzyme-linked immunoassay for the quantitative detection of IgG antibodies. The assay's sensitivity and 164 specificity for IgG quantification, according to the manufacturer, are 98.41% and 98.02%, 165 166 respectively. Quantitative results were calculated as a ratio of the extinction of the control or tested specimen over the extinction of the calibrator. Results were reported in standardized units for the 167 quantitative kits that included six calibrators to quantify the antibody concentration (i.e., DiaSino 168 169 units/mL). A value of <10 DU/mL was considered negative, and values >10 DU/mL were positive. 170

171 Data management

172 The linearity of the quantitative variables was evaluated by categorizing them into four categories using quartiles as cut-off values. Logistic regression analysis was conducted on the categorized 173 variables, and parameter estimates were observed for an increasing or decreasing trend. In case of 174 175 linear increase or decrease in the parameter estimates, linearity in the quantitative variable was assumed and used without modification. In the case of nonlinearity, a quartile was used to 176 categorize it. However, some quantitative variables were categorized considering research interest. 177 178 For instance, the number of days between the first dose of vaccine and quantification of antibody titer was categorized as 'after one month' and 'after two months' and between the second dose of 179 vaccine and quantification of antibody titer was categorized as 'after two months', 'after four 180

months' and 'after six months'. The number of days between the vaccination and the antibody titer
was achieved from the date of vaccination and sample collection. The prevalence estimates were
adjusted with the test kit performance (sensitivity and specificity), and the adjusted prevalence was
denoted as true prevalence.

185 Data analysis

186 In the study period, a total of 748 qualitative and quantitative test results were included in the 187 analysis. To evaluate the correlation and collinearity in the categorical and quantitative variables, 188 Cramer's V test, Spearman correlation coefficient, Chi-square test, t-test or ANOVA, where appropriate, was used. Variables with a significant association or a Spearman correlation 189 190 coefficient above 0.4 were regarded as correlated. The effects of different potential explanatory 191 variables on the binary outcome - presence/absence of anti-SARS-CoV-2 antibody, was evaluated using univariable and followed by multivariable logistic regression models. To select the final 192 193 multivariable model, all variables with a significant p-value in the univariable models were included in a model and a manually conducted backward selection strategy was followed by 194 deleting one variable at a time with the highest P-value. Interactions between all explanatory 195 variables (2 ways) were evaluated in the final model. Effect of variables on the mean titer of the 196 antibody was assessed by t-test and one way ANOVA. P-values <0.05 were considered as 197 significant throughout the analysis. STATA-IC 13 (StataCorp, California, USA) and GraphPad 198 199 Prism 7.00 for Windows (GraphPad Software, La Jolla, California, USA) were used for statistical 200 analyses and visualization.

201 Ethical approval and informed consent

202	Institutional e	ethical appr	oval was tal	ken from th	ne authorized	committee of	Chattogram	Veterinary

and Animal Sciences University (CVASU), Bangladesh [CVASU/Dir(R&E) EC/2020/212(1)].

204 **Results**

205 Sero-prevalence of SARS-CoV-2 infection

- SARS-CoV-2 IgG antibodies were detected in 498 (66.99%) of 748 individuals (Table 1).
- 207 Prevalence of anti-SARS-CoV-2 antibody (IgG) in different donor types along with vaccination
- 208 percentage is shown in Figure 1.
- 209

Table 1: Prevalence estimation in CMA							
Anti-SARS CoV-2	Total	Unadjust	ed	Test		Known	
antibody	population	seropreva		perform		positives	(RT-
		% (95%)	CI)	adjusted	1	qPCR po	sitive)
				seroprev	valence	(%)	
				% (95%	o CI)		
Present	498	66.58	(63.1-	66.99	(63.40-	91 (80.53)	
		70.0)		70.40)			
Absent	250	33.42	(30.1-	32.60	(29.20-	22 (19.47)	
		36.9)		36.19)			

210

211

Figure 1: Prevalence of anti-SARS-CoV-2 antibody (IgG) in different donor types along with
vaccinated percent.

214

215 Characteristics of study participants

From February -September 2021, we enrolled 748 CMA service providers (362 HCWs, 205

217 garments workers, 179 indoor/outdoor patients). Among them, 27.48% were garment workers, 150

218 (20.11%) hospital staff, 145 (19.44%) doctors, 148 (19.84%) outdoor patients, 67 (8.98%) nurses,

and 31 (4.16%) indoor patients. The majority (n=507; 67.96%) were males. In the total population,

- 220 292 (39.14%) did not receive any COVID-19 vaccine, 223 (29.89%) received the first dose of
- vaccine, and 231 (30.97%) received both doses of the vaccine. The responses regarding contact

with confirmed COVID-19 cases were: yes (342; 47.17%), no (307; 42.34%), and unknown (76;

- 10.48%). One hundred and ninety-seven (32.35%) participants had pre-existing medical
- conditions (Table 2).
- 225

Variables	Level	Total	Known	Asymptomatic
		population	positives	
			(RT-qPCR	
			positive)	
Donor type	Doctor	145 (19.44)	40 (35.40)	85 (16.13)
	Nurse	67 (8.98)	19 (16.81)	43 (8.16)
	Hospital staff	150 (20.11)	27 (23.89)	109 (20.68)
	Indoor patient	31 (4.16)	2 (1.77)	26 (4.93)

	Outdoor patient	148 (19.84)	21 (18.58)	109 (20.68)
	Garments	205 (27.48)	4 (3.54)	155 (29.41)
	worker			
Gender	Male	507 (67.96)	73 (65.18)	362 (68.69)
	Female	239 (32.04)	39 (34.82)	165 (31.31)
Age (year)	19 to 29	201 (26.91)	15 (13.27)	149 (28.27)
	30 to 35	184 (24.63)	30 (26.55)	123 (23.34)
	36 to 44	180 (24.10)	34 (30.09)	123 (23.34)
	45 to 84	182 (24.36)	34 (30.09)	132 (25.05)
Vaccination	No	292 (39.14)	11 (9.82)	222 (42.13)
	Only 1 st dose	223 (29.89)	38 (33.93)	153 (29.03)
	Both doses	231 (30.97)	63 (56.25)	152 (28.84)
Days passed after 1 st	14 to 30 days	45 (24.06)	8 (25.81)	30 (23.08; 16.1-
dose of vaccine				31.3)
	31 to 60 days	142 (75.94)	23 (74.19)	100 (76.92)
Days passed after	14 to 60 days	19 (8.26)	6 (9.38)	12 (8.00)
2 nd dose vaccine	61 to 120 days	86 (37.39)	20 (31.25)	60 (40.00)
	120 to 180 days	125 (54.35)	37 (59.38)	78 (52.00)
Days between PCR	21 to 60 days	-	17 (15.60)	-
test and antibody	61 to 120 days	-	16 (14.68)	-
test	121 to 180 days	-	23 (21.10)	-
	months			
	>180 days	-	53 (48.62)	-

Contact with	Yes	342 (47.17)	79 (71.17)	230 (45.19)
confirmed case	No	307 (42.34)	17 (15.32)	232 (45.58)
	Don't know	76 (10.48)	15 (13.51)	47 (9.23)
Family member	1 to 3	186 (26.23)	31 (29.52)	130 (25.79)
	4 to 6	443 (62.48)	64 (60.95)	321 (63.69)
	≥7	80 (11.28)	10 (9.52)	53 (10.52)
Taking	Yes	15 (2.13)	7 (6.42)	8 (1.63)
immunosuppressive	No	688 (97.87)	102 (93.58)	484 (98.37)
drugs				
Comorbidities	Yes	197 (32.35)	38 (37.25)	291 (68.79)
	No	412 (67.65)	64 (62.75)	132 (31.29)

226

227 SARS-CoV-2 antibody titer

Indoor/outdoor patients had the highest mean titer of 197.18 DU/mL, followed by HCWs (163.30 228 DU/mL) and garment workers (77.05 DU/mL) (p <0.001). The level (mean) of IgG-spike 229 antibodies in both dosage vaccine recipients was higher (255.46 DU/mL) than in those who 230 received one (159.08 DU/mL) or no doses (53.71 DU/mL) of the vaccine (p < 0.001). When the 231 participants had a contact with confirmed cases had a mean titer of 170.89 DU/mL, not known had 232 233 a titer of 160.05 DU/mL, and in case of noncontact 116.45 DU/mL (p < 0.001). The mean titer of different age groups was statistically significant; nevertheless, we removed this variable from 234 further analysis to minimize the bias due to vaccination strategy followed in Bangladesh (priority 235

- given to aged); details in **Table 3**. The changes in mean titer of IgG antibody across different time
- intervals of intervention (one and both doses of vaccination) is illustrated in Figure 2.
- 238

Table 3: Univariable analysis (ttest, one way ANOVA) to evaluate the mean difference of

 quantity of anti-SARS-CoV-2 antibody in serum samples

Variable	Level	Mean titer of	SD	P-value
		IgG (DU/ml)		
Doner type	Health worker	163.30	153.54	< 0.001
	Indoor/outdoor	197.18	147.04	
	patient			
	Garments	77.05	115.63	
	worker			
Gender	Female	140.09	151.36	0.31
	Male	151.83	148.38	
Age (year)	19 to 29	106.90	132.23	< 0.001
	30 to 35	151.16	157.71	
	36 to 44	160.85	143.08	
	45 to 84	176.95	155.92	
Vaccination	No	53.71	91.16	< 0.001
	Only 1st dose	159.08	161.05	
	Both doses	255.46	117.04	
Days passed after	31 to 60 days	131.39	152.08	0.10
1st dose of	14 to 30 days	175.10	164.09	

vaccine				
Days passed after	120 to 180 days	147.09	119.29	0.02
2nd dose vaccine	61 to 120 days	255.82	106.00	_
	14 to 60 days	324.42	128.42	_
Asymptomatic	No	190.01	161.93	< 0.001
	Yes	130.03	140.19	
Had COVID-19	No	191.69	142.70	0.005
confirmed status	Yes	244.87	159.74	_
Contact with	No	116.45	135.21	< 0.001
confirmed case	Yes	170.89	154.19	_
	Don't know	160.05	158.98	_
Taking	No	143.02	150.09	0.32
immunosuppressi	Yes	181.38	152.08	-
ve drugs				

239

- Figure 2: Evaluation of time effects of vaccines mean difference of quantitative anti-SARS-CoV-2
- 241 antibody (IgG) in serum samples.

242

243 Risk factor analysis

- 244 <u>Univariable analysis (χ^2 test, logistic regression) to evaluate the association of different variables</u>
- 245 with the seroprevalence of anti-SARS-CoV-2 antibody
- Indoor/outdoor patients amongst the different donor groups had a positivity rate of 81.37% (144
- of 179) compared to 68.99% (248 of 362) in the HCWs and 50.56% in the garments workers (104

- of 205); the difference was statistically significant (p < 0.001). Both doses of vaccine receivers
- showed significantly (p < 0.001) higher seropositivity than one dose or no vaccine receivers.
- 250 Similarly, contact with confirmed COVID-19 cases showed a higher odd of being seropositive as
- compared to noncontact (p=0.01) [OR= 1.59] (Table 4).
- 252

Variable	Level (n)	Presence of	TP (95%	OR	P-value
		IgG	CI of TP)		
			**		
Donor type	Health worker	248	68.99	Ref.	< 0.001
	(362)		(63.8-73.7)		
	Indoor/outdoor	144	81.37	1.8	
	patient (179)		(74.7-86.7)		
	Garments	104	50.56	0.47	
	worker (205)		(43.5-57.5)		
Gender	Female (239)	151	63.47	Ref.	0.15
			(56.9-69.5)		
	Male (507)	347	68.92	1.26	
			(64.6-72.9)		
Age (year)	19 to 29 (201)	114	56.76	Ref.	0.002
			(49.5-63.6)		

	30 to 35 (184)	119	65.01	1.39	
			(57.6-71.8)		
		100		2.00	-
	36 to 44 (180)	132	73.99	2.09	
			(66.8-80.1)		
	45 to 84 (182)	133	73.73	2.07	-
			(66.6-79.8)		
Vaccination	No (292)	131	44.47	Ref.	< 0.001
			(38.6-50.4)		
	Only 1st dose	137	61.66	1.95	-
	(223)		(54.8-68.0)		
	Both doses	229	100	140.72	-
	(231)		(98.4-		
			100.0)		
Days passed after	31 to 60 days	79	55.64	Ref.	0.29
1st dose of	(142)		(47.1-63.8)		
vaccine	14 to 30 days	29	64.78	1.44	-
	(45)		(49.6-77.5)		
Days passed after	120 to 180	123	99.9 (95.7-	-	-
2nd dose vaccine	days (125)		100)		
	61 to 120 days	86	100	-	
	(86)		(97.2-100)		
	14 to 60 days	19	100	-	
	(19)		(84.2-100)		

Asymptomatic	No (220)	160	73.36	Ref.	0.13
			(66.9-		
			79.03)		
	Yes (528)	355	67.66	0.76	
			(63.4-		
			71.68)		
Had COVID-19	No (144)	119	83.65	Ref.	0.66
confirmed status			(76.3-89.1)		
	Yes (113)	91	81.46	0.86	
			(72.9-87.9)		
Contact with	No (307)	187	61.11	Ref.	0.01
confirmed case			(55.3-66.6)		
	Yes (342)	244	71.93	1.59	
			(66.7-76.6)		
	Don't know	49	64.81	1.16	
	(76)		(53.1-75.0)		
Taking	No (688)	447	65.32	Ref.	0.20
immunosuppressi			(61.5-68.9)		
ve drugs	Yes (15)	12	80.91	2.15	
			(54.7-94.3)		

253 ******TP=True prevalence

255 <u>SARS-CoV-2 antibody-positive status in the study area</u>

²⁵⁴ Multivariable analysis (logistic regression) to determine the potential factors associated with

261	difference was statistically significant ($p < 0.001$) (Table 5).
260	chance of being positive (OR=174.02) than one dose (OR=2.34) or none dose receivers, and the
259	garments workers than HCWs ($p=0.01$). Further, both doses of vaccine receivers had a higher
258	being seropositive was 2.22 times higher in indoor/outdoor patients ($p=0.002$) and 1.69 times for
257	influencing the seropositivity of SARS-CoV-2 antibodies in the studied population. The chance of
256	The multivariable logistic regression model identified two potential factors that might be

262

Table 5: Output	from the final multi	variable logistic	regression model sho	wing the adjusted	
effect of potential factors on the seroprevalence of anti-SARS-CoV-2 antibody					
Variable	Level	OR	95% CI	P-value	
Doner type	Health worker	Ref.			
	Indoor/outdoor	2.22	1.33-3.68	0.002	
	patient				
	Garments	1.69	1.09-2.62	0.01	
	worker				
Vaccination	No	Ref.			
	Only 1st dose	2.34	1.56-3.50	<0.001	
	Both doses	174.02	41.46-730.40	<0.001	

263

264 **Discussion**

The overall adjusted seroprevalence estimate of SARS-CoV-2 antibodies was 66.99% (95% CI: 63.40%-70.4%) in CMA in this research which is slightly higher than a previous finding (64.1%) using an immunoassay test to detect antibodies in the Sitakunda sub-district (Chattogram district)

of Bangladesh from March to June 2021 [36]. Another research conducted by icddr'b between 268 October 2020 and February 2021 found a lower (55%) estimate in Chattogram than ours. During 269 the same study period, however, the adjusted seroprevalence in Dhaka, the capital of Bangladesh, 270 was 71% [37]. Thus, based on several investigations, it can be assumed that seropositivity in 271 272 Chattogram has been progressively increasing over time. The prevalence might have increased due 273 to either high infection levels or a positive response to the national immunization campaign in its early phases [38]. According to the findings, 68.99% HCWs and 81.37% indoor/outdoor patients 274 were seropositive. Indoor and outdoor patients were more likely than health professionals to be 275 276 seropositive, possibly due to the combined effect of lack of awareness and knowledge about COVID-19 among some of them and effect of vaccination as they might be were composed of a 277 mixed population of lower to upper socio-economic status and with different educational levels. 278 279 Tripathi et al., 2020 reported that HCWs were more educated of COVID-19 symptoms, incubation time, problems in high-risk patients, and had greater access to therapy than other residents (non 280 HCWs) [39]. In Navi Mumbai in May 2021, serosurveillance of anti-SARS-Cov-2 antibodies 281 among essential workers revealed that police personnel had a 72% seropositivity rate, whereas 282 HCWs had a 48% positivity rate [40]. Moreover, we observed that, among the garment workers, 283 284 just under 20% received vaccines and just above 50% were seropositive, which might have majorly been achieved from natural infections (Figure 1). It might indicate their lack of awareness about 285 disease transmission and vaccination. 286

We found that the IgG antibody was produced in 61.66% of the participants who received the first dose of COVID-19 vaccination. This number increased to 100% among individuals who received a second dose. In a study by Bayram et al., 2021, HCWs' seropositivity rates after the first and second doses of CoronaVac vaccination were found to be 77.8% and 99.6%, respectively [**41**].

Subsequently, when we quantified the antibody titer, we observed it higher in those who received the second dose than in those who received just the first. Detection of highly avid anti-S1/-RBD IgG, independent of the causal mechanism, is seen as a very positive indication and indicator of enhanced humoral immunity [42].

Human coronavirus infection may not always result in long-lasting antibody responses, with 295 296 antibody titers dropping over time [43]. The waning of antibody responses is an essential element 297 to consider while developing a coronavirus vaccine [44]. Our study showed that by the second month following the initial dose, the mean IgG titer in the body had dropped by nearly 25%. 298 299 However, the antibody's propensity to deteriorate with time was noteworthy. This study revealed that the available mean antibody titers that remained after two months of receiving the second dose 300 301 had dropped by roughly 21% by the fourth month, and within the sixth month the mean antibody titer was 147.09 DU/mL. So, it can be assumed that the body still retained considerable antibodies 302 against COVID-19 six months after receiving the second dose vaccine, though the threshold level 303 to prevent the virus is not known. 304

The underreporting of SARS-CoV-2 infection cases makes it difficult to assess the actual infection 305 burden. Limited testing, flaws in the reporting infrastructure, and a substantial proportion of 306 asymptomatic infections contribute to the underreporting [45]. Asymptomatic carriers spread 307 COVID-19, but the clinical characteristics, viral dynamics, and antibody responses of these 308 individuals are unknown [46]. According to our findings, 67.66% of the asymptomatic population 309 was seropositive where only 29.03 % of asymptomatic individuals received the first dose of 310 COVID-19 vaccine, and 28.84 % received the second dose too. According to various population-311 312 based studies, a considerable majority of seropositive people were asymptomatic or had no known encounter with a COVID-19 patient [47-49]. Meanwhile, the observation that asymptomatic 313

people had lower mean IgG levels than symptomatic people back up previous findings that asymptomatic carriers have a lesser humoral immune response to COVID-19 infection [**47,50**]. The study also revealed that people aged above 35 had a greater seroprevalence. Higher seroprevalence among adults could be associated with increased vaccination exposure. On January 26 of this year, the government began accepting registrations for the COVID-19 vaccine for persons aged 55 and up in the country [**51**]. In the second phase, the age limit was dropped to 40 years or more, and vaccination of youngsters aged 12-17 has recently begun in the country [**52**].

The latest and more deadly SARS-CoV-2 viral strains, as well as the possibility of losing immunity 321 322 with time after vaccination, have prompted health professionals to consider the need for boosters. Research on threshold titers giving protection and time intervals of declining immunity post-323 immunization for low-middle-income nations like Bangladesh are essential before launching 324 further booster doses. An important application of serological tests is to determine the antibody 325 responses generated upon SARS-CoV-2 infection and vaccination [53]. The continuation of this 326 327 study on those who received the second dose more than six months ago will provide an appropriate booster interval, risk population category, and overview of herd immunity. According to a recent 328 study conducted in the greater Chattogram division it is evident that administering the first dose 329 330 (Oxford-AstraZeneca) vaccine significantly reduces health risk during the COVID-19 infection phase [54]. So, it is evident that similar research is clamoring for justifications for booster 331 332 administration. Additionally, more research is required to assess the efficacy of booster doses. 333 Government and healthcare professionals must adopt COVID-19 vaccine booster dose utilization guidelines that consider the risks of fading immunity, new virus strains, and prioritizing vulnerable 334 335 groups.

Our study has several limitations, such as the fact that we only collected samples from hospitals and the garment industry, but the results would be more representative of the community if we included other groups. We could not compare immunological responses produced by different COVID-19 vaccine brands at the same post-vaccination interval since distinct COVID-19 vaccines were licensed and supplied to CMA at different times. We did not reveal the type and name of COVID-19 vaccines, whereas a sufficient fraction was not covered under the vaccination program, and we were concerned about an infodemic.

343

344 Acknowledgment

The authors acknowledge Bangladesh Institute of Tropical and Infectious Diseases (BITID), Chattogram General Hospital, Chittagong Medical University, Medical Center (Pvt.), Imperial Hospital Limited, Chattogram Asian Apparels Limited, Clifton Garments Limited, Bangladesh Garment Manufacturers and Exporters Association (BGMEA) Chattogram, and BGMEA Hospital and Diagnostic Center for providing samples and administrative support. The laboratory facilities were supported by the Dept. of Pathology and Parasitology, CVASU. The authors sincerely acknowledge the One Health Institute. CVASU for logistic support.

352

353 **Conflict of interest**

354 The authors have no potential conflict of interest.

355

356 Authors Contribution

JA: Conceptualization, methodology, project proposal writing, administration, data curation,
writing-original draft, review and editing. MSI: Conceptualization, methodology, project

359 administration, laboratory tasks, data visualization, writing-original draft, review and editing. MTUQ: Sample collection, data curation. AD: Sample collection, data curation. FMYH: 360 Laboratory tasks. MSI: Sample collection, data curation. TR: Sample collection, data curation. 361 SD: Data curation, writing review and editing. MAHC: Conceptualization, investigation, 362 methodology, supervision, and reviewing-final manuscript. GBD: Project investigation, fund 363 364 acquisition, and reviewing-final manuscript. SC: Conceptualization, investigation, methodology, supervision, data- validation, analysis, visualization, writing-original draft, and reviewing-final 365 manuscript. 366

367

368 **Funding Information**

369 The study was funded by the Director of Research & Extension, CVASU.

370

371 **References**

1. Rana EA, Chowdhury NS, Islam MS, Ara J, Nasrin SS, Dutta P, Bristi SZ, Nizami TA,

373 Chakraborty P, Siddiki AZ. Molecular detection and prevalence of SARS-CoV-2 during the

early outbreak in southern Bangladesh. International Journal of One Health. 2020;6(2):153-9.

2. Dhaka Tribune, First Coronavirus Case Confirmed in Chittagong, 6 Buildings in Lockdown.

- 376 2020 April 3. [Internet]. Available from:
- 377 https://archive.dhakatribune.com/bangladesh/nation/2020/04/03/covid-19-first-case-confirmed-

378 in-chittagong

379	3. Dhaka Tribune, Another Corona Virus Patient Dies in Chittagong. 2020 April 13. [Internet].
380	Available from: https://www.dhakatribune.com/health/coronavirus/2020/04/13/another-
381	coronavirus-patient-dies-in-chittagong
382	4. Goenka MK, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, Shah BB, Patil
383	VU, Rodge G, Khan U, Bandyopadhyay S. Seroprevalence of COVID-19 amongst health care
384	workers in a tertiary care hospital of a metropolitan city from India.
385	5. Vernet R, Charrier E, Grogg J, Mach N. A Quantitative ELISA Protocol for Detection of
386	Specific Human IgG against the SARS-CoV-2 Spike Protein. Vaccines. 2021 Jul;9(7):770.
387	6. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, Hayford K, Luquero FJ,
388	Mina MJ, Rodriguez-Barraquer I, Wu JT. Serology for SARS-CoV-2: Apprehensions,
389	opportunities, and the path forward. Science immunology. 2020 May 19;5(47):eabc6347.
390	7. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SS, Rezvani SM, Ghasempour Z,
391	Heidarzadeh A, Mansournia MA. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran,
392	April 2020. Emerging infectious diseases. 2021 Feb;27(2):636.
393	8. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, Weissberg Z,
394	Saavedra-Walker R, Tedrow J, Bogan A, Kupiec T. Covid-19 antibody seroprevalence in santa
395	clara county, california. International journal of epidemiology. 2021 Apr;50(2):410-9.
396	9. Gomes LR, Durans AM, Napoleão-Pêgo P, Waterman JA, Freitas MS, De Sá NB, Pereira
397	LV, Furtado JS, Aquino RG, Machado MC, Fintelman-Rodrigues N. Multiepitope Proteins for

- the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD
- Regions of SARS-CoV-2. Vaccines. 2021 Sep;9(9):986.
- 400 10. Freeman B, Lester S, Mills L, Rasheed MA, Moye S, Abiona O, Hutchinson GB, Morales-
- 401 Betoulle M, Krapinunaya I, Gibbons A, Chiang CF. Validation of a SARS-CoV-2 spike protein
- 402 ELISA for use in contact investigations and serosurveillance. Biorxiv. 2020 Jan 1.
- 403 11. Brown TS, Walensky RP. Serosurveillance and the COVID-19 epidemic in the US:
- 404 undetected, uncertain, and out of control. Jama. 2020 Aug 25;324(8):749-51.
- 12. Hossain M, Das SC, Raza MT, Ahmed IU, Eva IJ, Karim T, Chakraborty P, Gupta SD.
- 406 Immediate and post-COVID complications of symptomatic and asymptomatic COVID-19
- 407 patients in Bangladesh: a cross-sectional retrospective study. Asian Journal of Medical and
- 408 Biological Research. 2021 Jun 30;7(2):191-201.
- 13. Thomas SN, Altawallbeh G, Zaun CP, Pape KA, Peters JM, Titcombe PJ, Dileepan T, Rapp
- 410 MJ, Bold TD, Schacker TW, Arbefeville S. Initial determination of COVID-19 seroprevalence
- among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total
- 412 antibody ELISA. Clinical Biochemistry. 2021 Apr 1;90:15-22.
- 14. Lerner AM, Eisinger RW, Lowy DR, Petersen LR, Humes R, Hepburn M, Cassetti MC. The
 COVID-19 serology studies workshop: recommendations and challenges. Immunity. 2020 Jul
 14;53(1):1-5.

- 416 15. Wang H, Wiredja D, Yang L, Bulterys PL, Costales C, Röltgen K, Manalac J, Yee J,
- 417 Zehnder J, Shi RZ, Boyd SD. Case-Control Study of Individuals with Discrepant Nucleocapsid
- and Spike Protein SARS-CoV-2 IgG Results. Clinical Chemistry. 2021 Mar 15.
- 16. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E,
- 420 Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B. Humoral
- 421 immune response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020 Oct

422 29;383(18):1724-34.

423 17. Aljazeera, Coronavirus Pandemic, Bangladesh Starts COVID Vaccination Drive. 2021 Jan

424 28. [Internet]. Available from: https://www.aljazeera.com/news/2021/1/28/bangladesh-starts-

- 425 covid-vaccination-drive
- 426

427 18. Anadolu Agency, World, Asia-Pacific, Latest on CoronavirusOutbreak, Bangladesh Starts

428 Nationwide COVID Vaccination Drive. 2021 Feb 7. [Internet]. Available from:

429 https://www.aa.com.tr/en/asia-pacific/bangladesh-starts-nationwide-covid-vaccination-

430 drive/2136643

431 19. COVID-19 Vaccination Dashboard for Bangladesh, Health Emergency Control Center,

- 432 DHIS2, Surokkha App, **2022.** [Internet]. Available from:
- 433 http://103.247.238.92/webportal/pages/covid19-vaccination-update.php
- 434 20. Dhaka Tribune, Bangladesh Begins Booster Vaccination. 2021 Nov 28. [Internet]. Available
- 435 from: https://newsarchive.app/a/dhakatribune/2021/11/28/Bangladesh-begins-booster-

436 vaccination

437	21. Mahmud S, Mohsin M, Khan IA, Mian AU, Zaman MA. Knowledge, beliefs, attitudes and
438	perceived risk about COVID-19 vaccine and determinants of COVID-19 vaccine acceptance in
439	Bangladesh. PloS one. 2021 Sep 9;16(9): e0257096.

440 22. Bandyopadhyay S, Baticulon RE, Kadhum M, Alser M, Ojuka DK, Badereddin Y, Kamath

441 A, Parepalli SA, Brown G, Iharchane S, Gandino S. Infection and mortality of healthcare

workers worldwide from COVID-19: a systematic review. BMJ global health. 2020 Dec
1;5(12):e003097.

444 23. Bangladesh Medical Association. District wise total Number of Affected Doctor, Nurse &

445 Staff (COVID 19+) From 08/03/2020 till today on 28/09/2021. [Internet]. Available from:

446 https://bma.org.bd/covid-19/Total%20Affected%20Doctor,%20Nurse%20&%20Staff.pdf

447 24. Chen Q, Liang M, Li Y, Guo J, Fei D, Wang L, He LI, Sheng C, Cai Y, Li X, Wang J.

448 Mental health care for medical staff in China during the COVID-19 outbreak. The Lancet

449 Psychiatry. 2020 Apr 1;7(4): e15-6.

450 25. Mhango M, Dzobo M, Chitungo I, Dzinamarira T. COVID-19 risk factors among health
451 workers: a rapid review. Safety and health at work. 2020 Sep 1;11(3):262-5.

452 26. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M,

453 Knudsen AD, Christensen CE, Fogh K, Norsk JB, Andersen O. Risk of COVID-19 in health-care

454 workers in Denmark: an observational cohort study. The Lancet Infectious Diseases. 2020 Dec

455 1;20(12):1401-8.

- 456 27. Ehrlich H, McKenney M, Elkbuli A. Protecting our healthcare workers during the COVID-
- 457 19 pandemic. The American journal of emergency medicine. 2020 Jul 1;38(7):1527-8.
- 458 28. Shaw A, Flott K, Fontana G, Durkin M, Darzi A. No patient safety without health worker
- 459 safety. The Lancet. 2020 Nov 14;396(10262):1541-3.
- 460 29. Kontoangelos K, Economou M, Papageorgiou C. Mental health effects of COVID-19

461 pandemia: a review of clinical and psychological traits. Psychiatry investigation. 2020

462 Jun;17(6):491.

463 30. Khan AN, Ullah MR. Export scenario between Bangladesh and China: Opportunities of

464 Bangladesh in RMG Sector. Eur Sci J. 2017;13(28):299-320.

31. Hosen MS, Nafiujjaman M, Biswas FN. Garment employees are at higher risk than any other
workers in COVID-19 pandemic in Bangladesh. Caspian Journal of Health Research. 2020 Jan
10;5(1):1-2.

- 468 32. Dyal JW. COVID-19 among workers in meat and poultry processing facilities—19 states,
- April 2020. MMWR. Morbidity and mortality weekly report. 2020;69.
- 470 33. Marinaccio A, Guerra R, Iavicoli S. Work a key determinant in COVID-19 risk. The Lancet
- 471 Global Health. 2020 Nov 1;8(11): e1368.
- 472 34. Islam MS, Hasib FY, Nath C, Ara J, Nu MS, Fazal MA, Chowdhury S. Coronavirus disease
- 473 2019 and its potential animal reservoirs: A review. Health. 2021 Jul 1;7(2):171-81.

- 474 35. World Health Organization, Population-Based Age-Stratified Seroepidemiological
- 475 Investigation Protocol for Coronavirus 2019 (COVID-19) Infection. 2020 May. [Internet].
- 476 Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-

477 2020.2

- 478 36. Bhuiyan TR, Hulse JD, Hegde S, Akhtar M, Islam T, Khan ZH, Khan II, Rashid M, Rashid
- 479 R, Shirin T, Gurley ES. SARS-CoV-2 seroprevalence in Chattogram, Bangladesh before a
- 480 National Lockdown, March-April 2021. medRxiv. 2021 Jan 1.

481 37. icddr,b, news, Higher COVID-19 Seropositivity Observed Among Residents in Dhaka and

482 Chattogram. 2021 June 22. [Internet]. Available from: https://www.icddrb.org/news-and483 events/news?id=878

484 38. Ward H, Cooke G, Whitaker M, Redd R, Eales O, Brown JC, Collet K, Cooper E, Daunt A,

485 Jones K, Moshe M. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies

demonstrate impact of the second wave and of vaccine roll-out in England. MedRxiv. 2021 Jan1.

488 39. Tripathi R, Alqahtani SS, Albarraq AA, Meraya AM, Tripathi P, Banji D, Alshahrani S,

489 Ahsan W, Alnakhli FM. Awareness and preparedness of COVID-19 outbreak among healthcare

- 490 workers and other residents of South-West Saudi Arabia: a cross-sectional survey. Frontiers in
- 491 Public Health. 2020 Aug 18;8:482.

492 40. Maheshwari U, Sahai J, Hebbar V. Serosurveillance of Anti SARS-Cov-2 Antibodies among

493 Essential Workers in Navi Mumbai–A Single Centre Study. International Journal of Health

494 Sciences and Research. 2021;11(7):99-104.

30

- 495 41. Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies
 496 against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers. Journal
- 497 of medical virology. 2021 May 21.
- 498 42. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H, Krumbholz A.
- 499 Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with
- variants of concern or vaccination. Vaccines. 2021 Jul;9(7):700.
- 43. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
- 502 experimental coronavirus infection of man. Epidemiology & Infection. 1990 Oct;105(2):435-46.
- 44. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020 Apr
 14;52(4):583-9.
- 45. Bhattacharyya R, Kundu R, Bhaduri R, Ray D, Beesley LJ, Salvatore M, Mukherjee B.
- 506 Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and
- reconciling with seroprevalence estimates. Scientific reports. 2021 May 7;11(1):1-4.
- 46. Xiao T, Wang Y, Yuan J, Ye H, Wei L, Liao X, Wang H, Qian S, Wang Z, Liu L, Zhang Z.
- Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers.
- 510 Frontiers in Medicine. 2021;8.
- 47. Alkurt G, Murt A, Aydin Z, Tatli O, Agaoglu NB, Irvem A, Aydin M, Karaali R, Gunes M,
- 512 Yesilyurt B, Turkez H. Seroprevalence of coronavirus disease 2019 (COVID-19) among health
- care workers from three pandemic hospitals of Turkey. PloS one. 2021 Mar 3;16(3): e0247865.

- 48. Mukhtar A, Alfishawy M, Alkhatib E, Hosny M, Ollaek M, Elsayed A, Salem MR, Ghaith
- 515 D. Asymptomatic SARS-CoV-2 infection among healthcare workers in a non-COVID-19
- teaching university hospital. Journal of Public Health Research. 2021 Jun 24;10(3).
- 49. Selvaraju S, Kumar MS, Thangaraj JW, Bhatnagar T, Saravanakumar V, Kumar CP, Sekar
- 518 K, Ilayaperumal E, Sabarinathan R, Jagadeesan M, Hemalatha MS. Population-based serosurvey
- 519 for severe acute respiratory syndrome coronavirus 2 transmission, Chennai, India. Emerging
- 520 Infectious Diseases. 2021 Feb;27(2):586.
- 50. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K.
- 522 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature
- 523 medicine. 2020 Aug;26(8):1200-4.
- 524 51. Dhaka Tribune, Bangladesh Lowers Covid-19 Vaccine Age Limit to 18 Years. 2021 Oct 20.
- 525 [Internet]. Available from: https://www.dhakatribune.com/bangladesh/2021/10/20/bangladesh-
- 526 lowers-covid-19-vaccine-age-limit-to-18-years
- 527 52. Dhaka Tribune, COVID Vaccination Campaign for School Students. 2021 Nov 1. [Internet].
- 528 Available from: https://www.dhakatribune.com/bangladesh/2021/11/01/covid-vaccination-
- 529 campaign-for-school-students-kicks-off
- 530 53. Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020 Jun
- 531 5;368(6495):1060-1.

- 532 54. Rana EA, Dutta P, Islam MS, Nizami TA, Das T, Chowdhury S, Das GB. Severity
- assessment of single dose Oxford-AstraZeneca vaccinated individuals infected with SARS CoV-
- 534 2 in the Southeast Bangladesh. medRxiv. 2021 Jan 1.




Figure 1




Figure 2